Supernus Pharma (SUPN) Misses Q2 EPS by 144c
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Join SI Premium – FREE
Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of ($1.01), $1.44 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $219.1 million versus the consensus estimate of $205.63 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Starts Tier IV Inc (593A:JP) at Overweight
- Morgan Stanley Downgrades PWR Holdings Ltd. (PWH:AU) to Equalweight
- UBS Upgrades Celestica (CLS) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
